English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Membranoproliferative glomerulonephritis (MPGN) is an immune-mediated disease process, underlying 10%-20% of nephrotic syndrome cases in children and young adults.1 The Type I subtype (Classical MPGN) is the most common Hepatitis C Virus (HCV)-associated nephropathy.2 Still, though all MPGN subtypes (I,II,III) can slowly progress to end-stage renal disease (ERDS),3 the condition is uncommon enough to account for just 2.8% and 3.3% of all cases in pediatric dialysis patients and pediatric renal transplant recipients, respectively.4 This may explain, in part, why studies on the efficacies of various immunosuppressive agents in this condition are, on the whole, relatively limited.

Pathogenic mechanisms and direction of empirical studies: a retrospective on membranoproliferative glomerulonephritis